Alphatec Holdings（ATEC）株式概要
医療技術企業であるアルファテック・ホールディングスは、米国内外で脊椎疾患の外科的治療技術の設計、開発、改良を行っている。 詳細
ATEC Community Fair Values
Create NarrativeSee what 15 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Alphatec Holdings, Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$8.23 |
| 52週高値 | US$23.29 |
| 52週安値 | US$6.82 |
| ベータ | 0.97 |
| 1ヶ月の変化 | -21.47% |
| 3ヶ月変化 | -36.74% |
| 1年変化 | -34.05% |
| 3年間の変化 | -44.17% |
| 5年間の変化 | -43.40% |
| IPOからの変化 | -92.36% |
最新ニュース
Seeking Alpha • May 19
Alphatec - Slower Growth Seems Priced In Here
Summary Alphatec Holdings shares have dropped two-thirds YTD, now trading at just over 2x sales, reflecting sharply decelerating growth and persistent losses. Q1 2026 revenue grew only 14% to $192.1M, prompting a slight full-year sales guidance cut; adjusted EBITDA margins improved but remain heavily adjusted. Despite a $466M net debt load and ongoing dilution, Alphatec demonstrates real operating leverage, with manageable losses and a credible path toward profitability. Slowing topline growth and elusive margins temper enthusiasm, but current valuation appears compelling versus medtech peers, making Alphatec a speculative yet interesting play. Read the full article on Seeking Alpha
ナラティブの更新 • May 14
ATEC: 2026 Surgical Revenue Focus Will Support Future Upside Potential
Analysts have reduced their price target for Alphatec Holdings from about $24.62 to about $17.33 as they adjust assumptions for discount rate, revenue growth, profit margin, and future P/E in their models. What's in the News Alphatec Holdings issued earnings guidance for the fiscal year ending December 31, 2026, targeting total revenue of about $882 million, with surgical revenue expected to grow 17% as part of that outlook (corporate guidance).Recent updates
Seeking Alpha • May 19
Alphatec - Slower Growth Seems Priced In Here
Summary Alphatec Holdings shares have dropped two-thirds YTD, now trading at just over 2x sales, reflecting sharply decelerating growth and persistent losses. Q1 2026 revenue grew only 14% to $192.1M, prompting a slight full-year sales guidance cut; adjusted EBITDA margins improved but remain heavily adjusted. Despite a $466M net debt load and ongoing dilution, Alphatec demonstrates real operating leverage, with manageable losses and a credible path toward profitability. Slowing topline growth and elusive margins temper enthusiasm, but current valuation appears compelling versus medtech peers, making Alphatec a speculative yet interesting play. Read the full article on Seeking Alphaナラティブの更新 • May 14
ATEC: 2026 Surgical Revenue Focus Will Support Future Upside Potential
Analysts have reduced their price target for Alphatec Holdings from about $24.62 to about $17.33 as they adjust assumptions for discount rate, revenue growth, profit margin, and future P/E in their models. What's in the News Alphatec Holdings issued earnings guidance for the fiscal year ending December 31, 2026, targeting total revenue of about $882 million, with surgical revenue expected to grow 17% as part of that outlook (corporate guidance).
ナラティブの更新 • Apr 29
ATEC: 2026 Revenue Guidance Will Drive Constructive Upside Case
Analysts have kept their $28.00 price target for Alphatec Holdings unchanged, noting that only modest adjustments to assumptions around discount rate, revenue growth, profit margin and future P/E offset one another in their valuation work. What's in the News Alphatec Holdings reaffirmed earnings guidance for the fiscal year ending December 31, 2026, indicating no change to its previously communicated outlook.ナラティブの更新 • Apr 15
ATEC: 2026 Revenue Outlook Will Support Bullish Return Potential
Analysts have kept their $28.00 price target on Alphatec Holdings unchanged, citing updated assumptions that include a higher discount rate, stronger modeled revenue and profit margins, and a lower future P/E multiple that together balance out in their valuation work. What's in the News Alphatec Holdings reaffirmed earnings guidance for the fiscal year ending December 31, 2026, maintaining its outlook for that period.
ナラティブの更新 • Mar 31
ATEC: 2026 Revenue Outlook And Biologics Partnership Will Support Upside
Analysts have trimmed their price target for Alphatec Holdings from $22.00 to $20.00, citing updated assumptions for revenue growth, profit margins and future P/E that together point to a more measured long term outlook for the shares. What's in the News Reaffirmed earnings guidance for the fiscal year ending December 31, 2026, with total revenue expected to approximate $890 million, described as about $126 million or 17% above full year 2025 revenue (Corporate Guidance).ナラティブの更新 • Mar 17
ATEC: 2026 Revenue Outlook And Spine Biologics Partnership Will Support Upside
Analysts have left their $28.00 price target for Alphatec Holdings unchanged, citing a slightly higher assumed discount rate, a moderated revenue growth outlook, stronger projected profit margins, and a lower future P/E as key factors supporting the steady valuation. What's in the News Alphatec Holdings reaffirmed earnings guidance for the fiscal year ending December 31, 2026, with total revenue expected to approximate $890 million.ナラティブの更新 • Mar 03
ATEC: 2026 Revenue Outlook And Biologics Partnership Will Support Upside Potential
Analysts have adjusted their Alphatec Holdings target to $24.62, reflecting updated assumptions that combine slightly lower expected revenue growth with higher projected profit margins and a reduced future P/E multiple, while applying a somewhat higher discount rate. What's in the News Alphatec Holdings reaffirmed earnings guidance for the fiscal year ending December 31, 2026, with total revenue expected to approximate $890 million, described as about $126 million or 17% higher than full year 2025 revenue (company guidance).ナラティブの更新 • Feb 17
ATEC: 2026 Revenue Guidance And Spine Biologics Deal Will Drive Upside
Analysts have maintained their $28.00 price target for Alphatec Holdings, citing steady model adjustments to the discount rate, revenue growth, profit margin, and future P/E assumptions as reasons to hold their prior valuation line. What's in the News Alphatec Holdings issued revenue guidance for fiscal 2026, indicating expected total revenue of approximately $890m for the year ended December 31, 2026 (Corporate Guidance).ナラティブの更新 • Feb 03
ATEC: Partnership And 2026 Revenue Outlook Will Reshape Spine Biologics Opportunity
Analysts have raised their fair value estimate for Alphatec Holdings from $23.00 to $28.00, citing updated assumptions for discount rates, revenue growth, profit margins, and future P/E that they believe better reflect the company’s current outlook. What's in the News Alphatec Holdings issued revenue guidance for fiscal 2026, indicating expected total revenue of about $890 million compared to full year 2025 (Corporate Guidance).ナラティブの更新 • Jan 20
ATEC: Higher 2026 Revenue Outlook And New Partnership Will Support Upside
Analysts have lifted their price target on Alphatec Holdings from US$14.00 to US$22.00, citing updated assumptions around discount rate, revenue growth, profit margins and future P/E as the key drivers of the change. What's in the News Alphatec Holdings issued revenue guidance for fiscal 2026, indicating expected total revenue of approximately US$890 million for the year.分析記事 • Jan 06
Are Alphatec Holdings, Inc. (NASDAQ:ATEC) Investors Paying Above The Intrinsic Value?
Key Insights Alphatec Holdings' estimated fair value is US$17.32 based on 2 Stage Free Cash Flow to Equity Alphatec...ナラティブの更新 • Jan 06
ATEC: Higher 2025 Revenue Guidance Will Support A More Optimistic Outlook
Analysts have inched their price target for Alphatec Holdings higher to about $24.62 from $24.00, reflecting small tweaks to fair value estimates, discount rate assumptions, and a slightly higher future P/E multiple in their models. What's in the News Alphatec Holdings raised earnings guidance for the fiscal year ending December 31, 2025, indicating updated expectations for the business outlook.ナラティブの更新 • Dec 14
ATEC: Revenue Will Reach 760 Million As Outlook Remains Favorable
Analysts have modestly raised their price target on Alphatec Holdings by 0.25 dollars to 24.00 dollars, reflecting slightly higher long term valuation multiples despite only marginal tweaks to growth, margin and discount rate assumptions. What's in the News Alphatec Holdings raised its earnings guidance for fiscal 2025, now expecting total revenue to increase 24 percent to 760 million dollars, compared with the prior outlook of 742 million dollars (company guidance filing) Valuation Changes Fair Value Estimate has risen slightly to 24.00 dollars from 23.75 dollars, reflecting a modest uplift in long term valuation.ナラティブの更新 • Nov 29
ATEC: Revenue Will Reach $760 Million As Guidance Increases And Outlook Remains Steady
Analysts have maintained their fair value price target for Alphatec Holdings at $23.75, citing only minor adjustments to underlying financial assumptions along with a steady outlook for growth and profitability. What's in the News Alphatec Holdings raised its earnings guidance for the fiscal year ending December 31, 2025, reflecting increased confidence in the company's outlook (Key Developments).ナラティブの更新 • Nov 15
ATEC: Total Revenue Will Reach $760 Million Next Year
Narrative Update on Alphatec Holdings: Analyst Price Target Revision Analysts have increased their price target for Alphatec Holdings from $20.54 to $23.75. This change reflects revised financial assumptions and updated expectations for the company’s future performance.ナラティブの更新 • Nov 01
ATEC: Improved Margins And Revenue Projections Will Shape Future Performance
Analysts have raised their price target for Alphatec Holdings from $19.41 to $20.54 per share, citing improved profit margin forecasts and stronger projected revenue growth as key reasons for the increased valuation. What's in the News Alphatec Holdings, Inc.分析記事 • Oct 05
Not Many Are Piling Into Alphatec Holdings, Inc. (NASDAQ:ATEC) Just Yet
With a median price-to-sales (or "P/S") ratio of close to 2.8x in the Medical Equipment industry in the United States...ナラティブの更新 • Sep 20
Expanding Spine Care And Integrated Tech Will Drive Future Opportunities
The slight increase in Alphatec Holdings’ future P/E ratio reflects higher growth expectations, which has contributed to a modest rise in its consensus analyst price target from $18.95 to $19.41. What's in the News Raised full-year 2025 revenue guidance to $742 million, up 21% year-over-year, surpassing previous forecast of $734 million.分析記事 • Jul 28
Are Investors Undervaluing Alphatec Holdings, Inc. (NASDAQ:ATEC) By 43%?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Alphatec Holdings fair value estimate is US$19.10 Current...分析記事 • Jul 09
Should You Investigate Alphatec Holdings, Inc. (NASDAQ:ATEC) At US$11.60?
While Alphatec Holdings, Inc. ( NASDAQ:ATEC ) might not have the largest market cap around , it led the NASDAQGS...新しいナラティブ • May 27
Robotics And Minimally Invasive Techniques Will Expand Spine Care
Innovative spine solutions and expanding minimally invasive offerings position Alphatec for sustained revenue growth and margin expansion amid rising global spine care demand.分析記事 • May 11
Alphatec Holdings, Inc. (NASDAQ:ATEC) Stock Rockets 25% But Many Are Still Ignoring The Company
Alphatec Holdings, Inc. ( NASDAQ:ATEC ) shares have had a really impressive month, gaining 25% after a shaky period...分析記事 • Apr 20
Alphatec Holdings (NASDAQ:ATEC) Is Making Moderate Use Of Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...分析記事 • Mar 01
Alphatec Holdings, Inc. (NASDAQ:ATEC) Just Released Its Full-Year Results And Analysts Are Updating Their Estimates
Shareholders of Alphatec Holdings, Inc. ( NASDAQ:ATEC ) will be pleased this week, given that the stock price is up 18...分析記事 • Jan 18
Alphatec Holdings, Inc. (NASDAQ:ATEC) Stock Rockets 31% But Many Are Still Ignoring The Company
Despite an already strong run, Alphatec Holdings, Inc. ( NASDAQ:ATEC ) shares have been powering on, with a gain of 31...分析記事 • Dec 19
Here's Why Alphatec Holdings (NASDAQ:ATEC) Can Afford Some Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Dec 03
Alphatec: A Big Recovery
Summary Alphatec, a medtech company focused on spine solutions, has faced investor concerns due to continued losses, cash burn, and increasing debt despite revenue growth. Shares plunged 40% after Q2 earnings, but have recovered following the release of the third quarter results following management's comments about positive cash flow in Q4. Management's optimistic outlook is further backed up by significant improvement in EBITDA seen in 2025. Despite the positive reaction, Alphatec still needs to prove its ability to reduce debt and avoid further dilution while executing its growth plans. Read the full article on Seeking Alpha分析記事 • Nov 01
Alphatec Holdings, Inc. (NASDAQ:ATEC) Soars 50% But It's A Story Of Risk Vs Reward
Alphatec Holdings, Inc. ( NASDAQ:ATEC ) shareholders would be excited to see that the share price has had a great...分析記事 • Aug 29
Positive Sentiment Still Eludes Alphatec Holdings, Inc. (NASDAQ:ATEC) Following 38% Share Price Slump
The Alphatec Holdings, Inc. ( NASDAQ:ATEC ) share price has fared very poorly over the last month, falling by a...分析記事 • Aug 28
We Think Alphatec Holdings (NASDAQ:ATEC) Has A Fair Chunk Of Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Seeking Alpha • Aug 05
Alphatec: Creating Some Real Back Pain For Its Shareholders
Summary Alphatec Holdings, Inc. experiences continued losses and dilution due to a focus on growth over margin improvements, causing concern for shareholders. Despite strong top-line growth and low sales multiples, the company's losses, cash burn, and increasing debt are worrying investors. Shares plummeted 40% after the company's second quarter results, amidst concerns about debt and limited options to finance the cash needs. Read the full article on Seeking Alpha株主還元
| ATEC | US Medical Equipment | US 市場 | |
|---|---|---|---|
| 7D | 8.7% | 3.0% | -0.8% |
| 1Y | -34.1% | -18.3% | 27.1% |
業界別リターン: ATEC過去 1 年間で-18.3 % の収益を上げたUS Medical Equipment業界を下回りました。
リターン対市場: ATECは、過去 1 年間で27.1 % のリターンを上げたUS市場を下回りました。
価格変動
| ATEC volatility | |
|---|---|
| ATEC Average Weekly Movement | 12.8% |
| Medical Equipment Industry Average Movement | 8.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.2% |
安定した株価: ATECの株価は、 US市場と比較して過去 3 か月間で変動しています。
時間の経過による変動: ATECの weekly volatility ( 13% ) は過去 1 年間安定していますが、依然としてUSの株式の 75% よりも高くなっています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1990 | 913 | Pat Miles | www.atecspine.com |
医療技術企業であるアルファテック・ホールディングス社は、米国内外で脊椎疾患の外科的治療技術の設計、開発、進歩を行っている。同社はインプラント、器具、画像機器、スペアパーツを製造・販売している。全身画像を提供するEOS画像システム、筋電図、体性感覚誘発電位、運動誘発電位のモニタリングを自動化するSafeOp Neural InformatiX System、脊椎手術にナビゲーションとロボティクスを統合する術中システムValence、Sigma Prone TransPsoas (PTP) AccessおよびPTP Patient Positioning SystemなどのAlpha InformatiX製品プラットフォームを提供している。また、スプリットブレードリトラクター、術式に特化したアクセスシステムであるSigma-ALIF Access System、NanoTecとInvictusからなる脊椎インプラントと固定システム、高さの回復と安定化のための各種単体インプラントも提供している。さらに、3Dプロフューズ骨伝導性バイオスカフォールド、脱灰ヒト組織からなるアルファグラフト脱灰骨マトリックス（DBM）、骨欠損に合わせて成形可能な合成ミネラル・コラーゲン複合マトリックスであるBioCORE Moldable Bioactive Graftなどの生物製剤も提供している；AlphaGRAFT DBM Fibers（脱灰繊維）、AlphaGRAFT Cellular Bone Matrix (CBM)（成長因子を強化した細胞性骨基質）、AlphaGRAFT CBM（粒状、繊維状、構造状の形態で提供される）、Amnioshield Amniotic Tissue Barrier（脊椎外科バリア用途の同種移植片）などがある。同社は、独立した販売代理店と直接販売代理店のネットワークを通じて製品を販売している。同社は1990年に設立され、カリフォルニア州カールスバッドに本社を置いている。
Alphatec Holdings, Inc. 基礎のまとめ
| ATEC 基礎統計学 | |
|---|---|
| 時価総額 | US$1.27b |
| 収益（TTM） | -US$125.36m |
| 売上高(TTM) | US$787.08m |
1.6x
P/Sレシオ-10.1x
PER（株価収益率ATEC は割高か？
公正価値と評価分析を参照収益と収入
| ATEC 損益計算書（TTM） | |
|---|---|
| 収益 | US$787.08m |
| 売上原価 | US$234.72m |
| 売上総利益 | US$552.37m |
| その他の費用 | US$677.73m |
| 収益 | -US$125.36m |
直近の収益報告
Mar 31, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | -0.82 |
| グロス・マージン | 70.18% |
| 純利益率 | -15.93% |
| 有利子負債／自己資本比率 | 3,140.9% |
ATEC の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/21 21:12 |
| 終値 | 2026/05/21 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Alphatec Holdings, Inc. 11 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。26
| アナリスト | 機関 |
|---|---|
| Matthew Miksic | Barclays |
| Caitlin Cronin | Canaccord Genuity |
| Tao Levy | Deutsche Bank |